A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial

NCT06026254 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

2

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor, Adult

Interventions

DRUG: IMSA101
DRUG: Immune Checkpoint Inhibitor

Sponsor

ImmuneSensor Therapeutics Inc.